LEVOCETIRIZINE

'Levocetirizine' (as levocetirizine dihydrochloride) is a third generation non-sedative antihistamine, developed from the second generation antihistamine cetirizine. Chemically, levocetirizine is the active enantiomer of cetirizine. Levocetirizine works by blocking histamine receptors. It does not prevent the actual release of histamine from mast cells, but prevents it binding to its receptors. This in turn prevents the release of other allergy chemicals and increased blood supply to the area, and provides relief from the typical symptoms of hayfever.
It is claimed to be more effective and with fewer side effects than the second generation drugs.

Contents

History & formulations

Side Effects

Research

Availability

External links

References

History & formulations

Levocetirizine was first launched in 2001 by Belgian pharmaceutical company UCB with the brand name 'Xyzal®' in the UK, Austria and France, 'Xuzal®' in Mexico and 'Xusal®' and 'Xozal®' elsewhere in Europe. In India, levocetirizine is marketed by GlaxoSmithKline under the brand name 'Vozet®'.
It is available as 5mg strength tablets.

Side Effects

Levocetirizine is called a non-sedating antihistamine as it does not enter the brain in significant amounts, and is therefore unlikely to cause drowsiness. However, some people may experience some slight sleepiness or fatigue. It should be used with caution when working with machines. You should also make sure you know how this medicine affects you before you perform potentially hazardous activities.

Research

Latest research shows levocetirizine reduces asthma attacks by 70% in children.^[1]

Availability

Although the drug was only authorized by the US FDA on 25 May 2007 U.S., it is already available in most European countries. Based on previous pricing patterns for new drugs, it will likely enter the market at a higher price than currently available third and second generation antihistamines.

External links

References

1. http://www.medicalnewstoday.com/medicalnews.php?newsid=48201/ levocetirizine prevents asthma